Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
ARS Pharmaceuticals
SPRY
ARS Pharmaceuticals
Costs And Regulation Will Hinder Prospects But Demand Will Recover
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
26 Aug 25
Updated
26 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$25.00
46.2% undervalued
intrinsic discount
26 Aug
US$13.44
1Y
-2.2%
7D
-7.9%
Loading
1Y
-2.2%
7D
-7.9%
Author's Valuation
US$25.0
46.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$25.0
46.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-62m
242m
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue US$241.9m
Earnings US$39.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
42.21%
Biotech revenue growth rate
11.84%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$39.31m
Earnings '28
x
79.75x
PE Ratio '28
=
US$3.13b
Market Cap '28
US$3.13b
Market Cap '28
/
103.92m
No. shares '28
=
US$30.17
Share Price '28
US$30.17
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$24.78
Fair Value '25
